Tareq Abadl/LinkedIn
May 29, 2026, 13:49
Tareq Abadl: The Rh Blood Group System – Meet the 5 Antigens That Matter Most
Tareq Abadl, Medical Lab Specialist, shared a post on LinkedIn:
“The Rh Blood Group System – Meet the 5 Antigens That Matter Most
You know Rh+ and Rh−.
The Rh system has over 50 antigens — but D, C, c, E, and e are the 5 that account for most clinically significant transfusion complications.
D Antigen
- Frequency: ~85% of population
- Antibody: Anti-D (IgG)
- Most immunogenic Rh antigen
- Causes: severe HTR and HDFN
- Defines Rh+ vs Rh−
C Antigen
- Frequency: ~70%
- Antibody: Anti-C (IgG)
- Causes: mild-moderate HTR and HDFN
c Antigen
- Frequency: ~80%
- Antibody: Anti-c (IgG)
- Causes: HTR and HDFN
- Second most clinically significant after anti-D
E Antigen
- Frequency: ~30%
- Antibody: Anti-E (IgG)
- Causes: HTR and HDFN
e Antigen
- Frequency: ~98% — most common Rh antigen!
- Antibody: Anti-e (IgG) — rare but significant
- Causes: HTR and HDFN
Immunogenicity Order — Strongest to Weakest: D, E, C, c, and e
Key Rule:
All Rh antibodies are IgG, react best at 37°C, and should be considered potential causes of hemolytic transfusion reactions and HDFN.”
Other posts featuring Tareq Abadl on Hemostasis Today.
-
May 29, 2026, 13:39Kalyan Roy: Hematopoietic Stem Cell Transplantation in Thalassaemia
-
May 29, 2026, 12:53Wolfgang Miesbach: The Risk of Deskilling in Modern AI Assisted Medicine
-
May 29, 2026, 12:20Pall T. Onundarson: Is Anonymous Peer Review Always Objective
-
May 29, 2026, 11:59Jolene Ng: New Review Explores the Pathophysiology of Pre-Eclampsia
-
May 29, 2026, 11:44Lynne Baird: Why Expanding Bleed Control Kits Across Public Transport Matters
-
May 29, 2026, 11:30Rumbidzai Mushambi: When ‘Just Hormones’ Delays Real Diagnosis
-
May 29, 2026, 09:53Yassin Taher: Recognizing Clonal Eosinophilic Disorders in Pediatric Hypereosinophilic Syndrome
-
May 29, 2026, 09:52Sergio Emanuel Kaiser: Ruvonoflast and a New Anti-Inflammatory Strategy for Residual Cardiovascular Risk
-
May 29, 2026, 09:50Maria Symiakaki: Advancing Cardiovascular Prevention at the 2026 Congress of the European Atherosclerosis Society